What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cancer
Michael I. Nishimura mostly deals with Immunology, T cell, Antigen, T-cell receptor and Molecular biology.
As a member of one scientific family, Michael I. Nishimura mostly works in the field of Immunology, focusing on Cancer and, on occasion, Oncology.
Michael I. Nishimura has researched T cell in several fields, including Cytotoxic T cell, Major histocompatibility complex and Cell biology.
Epitope and MART-1 Antigen are the core of his Antigen study.
His T-cell receptor research integrates issues from Cancer research and Tumor antigen.
His Molecular biology study incorporates themes from Interleukin 21 and CTL*.
His most cited work include:
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (941 citations)
- Cancer classification using the Immunoscore: a worldwide task force (525 citations)
- Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity (385 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include T cell, T-cell receptor, Immunology, Antigen and Cancer research.
The T cell study combines topics in areas such as CTL*, CD8, Avidity and Effector.
His studies deal with areas such as Molecular biology, Adoptive cell transfer, Receptor and Cell biology as well as T-cell receptor.
His Immunology research incorporates elements of Cytotoxic T cell and Cancer.
He interconnects Virology, Melanoma and Immunotherapy in the investigation of issues within Antigen.
The concepts of his Cancer research study are interwoven with issues in Protein kinase B, Cancer cell, Cancer immunotherapy, MHC class I and Cell therapy.
He most often published in these fields:
- T cell (60.00%)
- T-cell receptor (58.52%)
- Immunology (54.07%)
What were the highlights of his more recent work (between 2017-2021)?
- T cell (60.00%)
- Cancer research (30.37%)
- T-cell receptor (58.52%)
In recent papers he was focusing on the following fields of study:
Michael I. Nishimura mainly investigates T cell, Cancer research, T-cell receptor, Immunotherapy and Adoptive cell transfer.
T cell is a primary field of his research addressed under Immunology.
His work on Immune system, Umbilical cord and Cord blood as part of general Immunology study is frequently connected to Interleukin 13, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His research integrates issues of Cell therapy, Receptor, Transgene and Cell biology in his study of T-cell receptor.
His studies examine the connections between Immunotherapy and genetics, as well as such issues in Melanoma, with regards to Cancer immunology, Immunologic evaluation, Chemotherapy and Clinical trial.
His Adoptive cell transfer research is multidisciplinary, relying on both Tumor microenvironment and Interferon.
Between 2017 and 2021, his most popular works were:
- CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response (94 citations)
- T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. (33 citations)
- Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling (15 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Cancer
Michael I. Nishimura focuses on T cell, Cell biology, Immunotherapy, Cancer research and Adoptive cell transfer.
Michael I. Nishimura studies T-cell receptor, a branch of T cell.
The various areas that he examines in his Immunotherapy study include Combined Modality Therapy, Melanoma and Oncology.
His Cancer research research incorporates themes from FOXO1, Protein kinase B and Breast cancer, Triple-negative breast cancer.
The Adoptive cell transfer study combines topics in areas such as Tumor microenvironment, Interferon, PI3K/AKT/mTOR pathway and Programmed cell death.
His Antigen research is multidisciplinary, incorporating elements of Receptor and Plasma protein binding.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
